Credit crunch could affect global healthcare, warns AstraZeneca's CEO
This article was originally published in Scrip
As share prices continue to tumble around the world, at least one top drug company executive is clear in his view about the spiralling global financial crisis. "While we do not expect a direct effect on our business, there will certainly be significant cost pressures on governments which pay for healthcare," AstraZenecaCEO David Brennan believes.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.